On Tuesday, Synthesis Energy Systems, Inc. (NASDAQ:SYMX)’s shares declined -16.30% to $1.54.
Synthesis Energy Systems, Inc. (SYMX) will release financial results for its fiscal 2015 third quarter ended March 31, 2015, on Tuesday, May 12, 2015. SES’s President and CEO, Robert W. Rigdon, and CFO and Corporate Secretary, Roger L. Ondreko, will hold a conference call to review the Company’s financial results and provide an update on corporate developments starting at 4:15 p.m. EDT on May 12.
Synthesis Energy Systems, Inc., a development stage energy and gasification technology company, provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide.
IDEXX Laboratories, Inc. (NASDAQ:IDXX)’s shares dropped -17.07% to $133.56.
IDEXX Laboratories, Inc. (IDXX) stated revenues for the first quarter of 2015 of $382 million, an enhance of 6% contrast to the preceding year period. Impacts from the strengthening of the US dollar reduced stated revenue growth by 6%. Normalized organic revenue growth1,2 for the quarter was 11.4%, supported by solid growth across business segments. Earnings per diluted share (“EPS”) was $0.98 for the quarter, an enhance of 10% contrast to the preceding year period despite a negative 8% growth impact related to changes in net foreign exchange rates.
IDEXX Laboratories, Inc., together with its auxiliaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
At the end of Tuesday’s trade, Endurance International Group Hldgs Inc (NASDAQ:EIGI)‘s shares dipped -10.21% to $19.70.
Endurance International Group Hldgs Inc (EIGI) declared that Hari Ravichandran, founder and chief executive officer, will present at the 2015 Jefferies Technology, Media & Telecom Conference in Miami on Tuesday, May 12, 2015 at 2:00 p.m. EDT.
Endurance International Group Holdings, Inc., together with its auxiliaries, provides cloud-based platform solutions for small-and medium-sized businesses worldwide. It offers domain registration, administration, and resale services; proprietary, third-party, and open source Website building tools and design services that enable subscribers with varying degrees of technical sophistication to create a customized Web presence; Web hosting services, counting entry-level shared hosting, and virtual private server and dedicated hosting services; malware protection solutions to protect subscribers Websites from viruses, malicious code, and other threats; and backup control solutions that enable subscribers to plan, maintain, manage, and restore backups of their online data and Websites to meet their particular business needs. T
Advaxis, Inc. (NASDAQ:ADXS), ended its Tuesday’s trading session with -8.98% loss, and closed at $19.37.
Advaxis, Inc. (ADXS) declared that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,012,141 with composition of matter claims covering the Advaxis product candidate, ADXS-PSA, and U.S. Patent No. 9,017,660 with methods of use claims covering the Advaxis product candidate, ADXS-HER2.
The first patent, which will expire on November 26, 2028, covers constructs related to ADXS-PSA, Advaxis’s Lm-LLO immunotherapy candidate being developed to address prostate cancer. Specifically, the patent provides composition of matter protection for a recombinant Listeria strain encoded with recombinant fusion peptide of KLK3 peptide linked to non-KLK3 peptide.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
